- P7C3-A20
-
- $0.00 / 1g
-
2025-01-03
- CAS:1235481-90-9
- Min. Order: 1g
- Purity: 99% min
- Supply Ability: 20 tons
- P7C3-A20
-
- $29.00 / 5mg
-
2024-11-19
- CAS:1235481-90-9
- Min. Order:
- Purity: ≥98%
- Supply Ability: 10g
- P7C3-A20
-
- $1.00 / 1ASSAYS
-
2019-09-06
- CAS:1235481-90-9
- Min. Order: 1ASSAYS
- Purity: 95%~99%
- Supply Ability: per week:100kg
|
| P7C3-A20 Basic information |
Product Name: | P7C3-A20 | Synonyms: | P7C3-A20 3,6-Dibromo-beta-fluoro-N-(3-methoxyphenyl)-9H-carbazole-9-propanamine;P7C3-A20, >=98%;P7C3-A20;N-(3-(3,6-DIBROMO-9H-CARBAZOL-9-YL)-2-FLUOROPROPYL)-3-METHOXYANILINE;3,6-Dibromo-beta-fluoro-N-(3-methoxyphenyl)-9H-carbazole-9-propanamine;CS-2365;9H-Carbazole-9-propanamine, 3,6-dibromo-β-fluoro-N-(3-methoxyphenyl)- | CAS: | 1235481-90-9 | MF: | C22H19Br2FN2O | MW: | 506.21 | EINECS: | | Product Categories: | Inhibitors | Mol File: | 1235481-90-9.mol | |
| P7C3-A20 Chemical Properties |
Boiling point | 641.3±55.0 °C(Predicted) | density | 1.57±0.1 g/cm3(Predicted) | storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | solubility | Soluble in DMSO (40 mg/ml) | pka | 3.25±0.50(Predicted) | form | solid | color | Off-white | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| P7C3-A20 Usage And Synthesis |
Description | P7C3-A20 is a derivative of P7C3 (Item No. 16682) that has proneurogenic and neuroprotective activity. It increases proliferation in the subgranular zone (SGZ) of the adult mouse dentate gyrus in a dose-dependent manner when administered at doses ranging from 0.1 to 10 μM. It also protects U2OS cells from calcium-induced mitochondrial dissolution. In a rat model of traumatic brain injury, P7C3-A20 (10 mg/kg, i.p., twice daily for one week) decreases contusion volume, increases proliferation in the SGZ, and decreases the latency to reach the platform in the Morris water maze to sham surgery control levels. It also prevents or reverses dopaminergic cell death and motor deficits in a 6-OHDA rat model of Parkinson's disease. | References | LoCoco et al. (2017), Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy; Elife, 6 e29626
Blaya et al. (2014), Neuroprotective efficacy of a proneurigenic compound after traumatic brain injury; Neurotrauma, 31 476
Vázquez-Rosa et al. (2020), P7C3-A20 treatment one year after TBI in mice repairs the blood-brain barrier, arrests chronic neurodegeneration, and restores cognition; Proc. Natl. Acad. Sci. USA, 117 27667
Bai et al. (2020), The Small Molecule P7C3-A20 Exerts Neuroprotective Effects in a Hypoxic-ischemic Encephalopathy Model via Activation of PI3K/AKT/GSK3? Signaling; Neuroscience, 441 197
Oku et al. (2017), P7C3 Suppresses Neuroinflammation and Protects Retinal Ganglion Cells of Rats from Optic Nerve Crush; Invest. Ophthamol. Vis. Sci., 58 4877 |
| P7C3-A20 Preparation Products And Raw materials |
|